The study used data from the Veterans Affairs (VA) Health Care System database. Men included in the analysis were age 40 years or older, had a baseline PSA at or below 4.0 ng/ml, were not taking 5- alpha reductase inhibitors (such as Avodart, Proscar or Propecia) and had not been previously diagnosed with prostate cancer. The men were followed for 4 years. The final analysis included 41,250 Caucasian and African-American men. Approximately 3% of the men had prostate cancer, and mean time to prostate cancer diagnosis was 2 years.
The ideal PSA threshold for predicting future prostate cancer in Caucasian men was 2.5 ng/ml. The ideal threshold for African-American men was even lower at 1.9 ng/ml. Across all patients, the optimal PSA threshold was 2.4 ng/ml.
The study was published online ahead of print in World Journal of Urology.